Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Dec 27;7(52):86621-86629.
doi: 10.18632/oncotarget.13361.

Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer

Wei Zhang  1 , Zhifen Zhang  1
Affiliations
Meta-Analysis

Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer

Wei Zhang et al. Oncotarget. .

Abstract

Recent studies explored XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer (OC) risk. However, the association between these two single nucleotide polymorphisms and OC risk remains conflicting. Thus, we conducted a comprehensive systematic review and meta-analysis to investigate the association. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. 15 case-control studies published in 11 papers including 4,757 cases and 8,431 controls were included in this meta-analysis. No associations were obtained between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk. Stratification analyses of Hardy-Weinberg equilibrium status indicated that rs3218536 polymorphism was associated with the decreased risk of OC when in analysis of combined HWE positive studies. In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.

Keywords: ERCC2; XRCC2; meta-analysis; ovarian cancer; single nucleotide polymorphism.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1. Selection for eligible citations included in this meta-analysis
Figure 2
Figure 2. Forest plot shows odds ratio for the associations between ERCC2 rs13181 polymorphism and OC risk (Dominant model)
Figure 3
Figure 3. Stratification analyses by source of control between ERCC2 rs13181 polymorphism and OC risk (Dominant model)
Figure 4
Figure 4. Sensitivity analysis about XRCC2 rs3218536 polymorphism and OC risk (Recessive model)
Figure 5
Figure 5. Sensitivity analysis about ERCC2 rs13181 polymorphism and OC risk (Dominant model)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, et al. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British journal of cancer. 2009;100:412–420. - PMC - PubMed
    1. Slotman BJ, Rao BR. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer research. 1988;8:417–434. - PubMed
    1. Romero I, Bast RC., Jr Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593–1602. - PMC - PubMed
    1. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Experimental biology and medicine. 2004;229:546–552. - PubMed
    1. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future oncology. 2006;2:257–274. - PubMed

MeSH terms

Substances